Continuous Glucose Monitoring Systems Market By Component, By Demography, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

Description

List of Tables

The continuous glucose monitoring systems market was valued at $6,626.6 million in 2021, and is estimated to reach $31,708.2 million by 2031, growing at a CAGR of 17.0% from 2022 to 2031.The continuous glucose monitoring systems (CGMs) market has emerged as a promising diabetes management tool for monitoring all types of diabetic patients. CGMs are mainly used by patients suffering from hypo and hyperglycemic conditions. There are several different types of CGM systems available in the market, each with its own set of features and benefits such as interstitial fluid CGMs, blood glucose CGMs, and hybrid closed loop CGMs. These systems offer various advantages such as improved glucose control, reduced need for fingerstick testing, increased awareness of glucose patterns, and improved quality of life.

The continuous glucose monitoring systems market growth is driven by increase in number of patients suffering from diabetes; rise in technological advancements such as the development of miniaturized and wearable devices that can provide real-time glucose readings; and increase in patient awareness about be benefits of CGMs. The rise in prevalence of diabetes propels high adoption of CGMs for monitoring glucose levels. The sensor is implanted in the layer of skin which measure glucose levels in the interstitial fluid and a receiver displays the readings. For instance, according to International Diabetes Federation (IDF), about 537 million adults are living with diabetes in 2021, across the globe. In addition, as per the same source, over 3 in 4 adults with diabetes live in low and middle-income countries such as India and China. Thus, rise in the prevalence of diabetes has resulted in increased demand for CGMs, which, in turn, contribute to the market growth.

Furthermore, increase in government initiatives and reimbursement policies are the key factors that boost the market growth. For instance, the Australian Government has implemented the continuous glucose monitoring (CGM) Initiative as part of the National Diabetes Services Scheme (NDSS) to provide access to fully subsidized Dexcom CGMs for eligible people with Type 1 diabetes. This initiative is designed to improve the quality of life for people with Type 1 diabetes and reduce the risk of complications associated with the condition. By providing access to fully subsidized CGMs, the government is helping to make these devices more widely available and accessible to people with Type 1 diabetes. Furthermore, rise in funding activities to conduct the clinical evaluations of CGMs, further contribute towards the market growth. For instance, European Commission's Horizon 2020 program provided funding of $2.85 million for the continued development of non-invasive touch glucose monitoring technology, GlucoBeam. Therefore, such initiatives taken by government supports the company to continue the research and testing of novel CGMs, which, in turn, boost the market growth.

However, the high cost of CGM systems, and complexity of devices limit the adoption of CGMs, which, in turn, restrains the market growth.

On the other hand, increased demand of medical devices in the developed countries such as the U.S., Canada, and rest of world and growth potential in emerging markets expected to create immense opportunities for CGMs during the forecast period.

The continuous glucose monitoring systems market is segmented on the basis of component, demography, end user, and region. On the basis of component, the market is classified into sensors and transmitters & receivers. On the basis of demography, the market is segmented into child population (≤14 years) and adult population (>14 years). On the basis of end user, the market is classified into hospitals & clinics, home healthcare, and others. The others include ambulatory settings and diagnostic center.

Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, Netherlands, Norway, Sweden, Denmark, Finland, and rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, New Zealand, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, Venezuela, Argentina, and rest of LAMEA).

Major key players that operate in the global continuous glucose monitoring systems market are: A. Menarini, Diagnostics S.r.l, Abbott Laboratories, DexCom, Inc., F. Hoffman-La Roche Ltd, GlySens Incorporated, Johnson & Johnson, Medtronic plc, Novo Nordisk A/S, Senseonics, and Ypsomed AG.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the continuous glucose monitoring systems market analysis from 2021 to 2031 to identify the prevailing continuous glucose monitoring systems market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the continuous glucose monitoring systems market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global continuous glucose monitoring systems market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Demography

Child Population
Adult Population

By End User

Home healthcare
Others
Hospital and Clinics

By Component

Transmitters and Receivers
Sensors

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Russia
- Spain
- Netherlands
- Norway
- Sweden
- Denmark
- Finland
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- New Zealand
- Philippines
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Venezuela
- Argentina
- Rest of LAMEA

Key Market Players

Medtronic plc
DexCom, Inc.
Johnson & Johnson
F. Hoffman-La Roche Ltd
GlySens Incorporated
Novo Nordisk A/S
Abbott Laboratories
Senseonics
A. Menarini Diagnostics S.r.l
Ypsomed AG

Product Code: A01466

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in number of people suffering from diabetes
  - 3.4.1.2. Benefits of CGMs over conventional glucose monitoring devices
  - 3.4.1.3. High adoption rate of CGMs in home healthcare and ICUs
- 3.4.2. Restraints
  - 3.4.2.1. Adverse effects associated with CGMs
  - 3.4.2.2. High cost of CGMs
- 3.4.3. Opportunities
  - 3.4.3.1. High undiagnosed patient population
  - 3.4.3.2. Technological advancement in CGMs
3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Sensors
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Transmitters and Receivers
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Child Population
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Adult Population
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital and Clinics
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Home healthcare
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Component
- 7.2.3. Market size and forecast, by Demography
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Component
  - 7.2.5.1.3. Market size and forecast, by Demography
  - 7.2.5.1.4. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Component
  - 7.2.5.2.3. Market size and forecast, by Demography
  - 7.2.5.2.4. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Component
  - 7.2.5.3.3. Market size and forecast, by Demography
  - 7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Component
- 7.3.3. Market size and forecast, by Demography
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Component
  - 7.3.5.1.3. Market size and forecast, by Demography
  - 7.3.5.1.4. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Component
  - 7.3.5.2.3. Market size and forecast, by Demography
  - 7.3.5.2.4. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Component
  - 7.3.5.3.3. Market size and forecast, by Demography
  - 7.3.5.3.4. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Component
  - 7.3.5.4.3. Market size and forecast, by Demography
  - 7.3.5.4.4. Market size and forecast, by End User
  - 7.3.5.5. Russia
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Component
  - 7.3.5.5.3. Market size and forecast, by Demography
  - 7.3.5.5.4. Market size and forecast, by End User
  - 7.3.5.6. Spain
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Component
  - 7.3.5.6.3. Market size and forecast, by Demography
  - 7.3.5.6.4. Market size and forecast, by End User
  - 7.3.5.7. Netherlands
  - 7.3.5.7.1. Key market trends, growth factors and opportunities
  - 7.3.5.7.2. Market size and forecast, by Component
  - 7.3.5.7.3. Market size and forecast, by Demography
  - 7.3.5.7.4. Market size and forecast, by End User
  - 7.3.5.8. Norway
  - 7.3.5.8.1. Key market trends, growth factors and opportunities
  - 7.3.5.8.2. Market size and forecast, by Component
  - 7.3.5.8.3. Market size and forecast, by Demography
  - 7.3.5.8.4. Market size and forecast, by End User
  - 7.3.5.9. Sweden
  - 7.3.5.9.1. Key market trends, growth factors and opportunities
  - 7.3.5.9.2. Market size and forecast, by Component
  - 7.3.5.9.3. Market size and forecast, by Demography
  - 7.3.5.9.4. Market size and forecast, by End User
  - 7.3.5.10. Denmark
  - 7.3.5.10.1. Key market trends, growth factors and opportunities
  - 7.3.5.10.2. Market size and forecast, by Component
  - 7.3.5.10.3. Market size and forecast, by Demography
  - 7.3.5.10.4. Market size and forecast, by End User
  - 7.3.5.11. Finland
  - 7.3.5.11.1. Key market trends, growth factors and opportunities
  - 7.3.5.11.2. Market size and forecast, by Component
  - 7.3.5.11.3. Market size and forecast, by Demography
  - 7.3.5.11.4. Market size and forecast, by End User
  - 7.3.5.12. Rest of Europe
  - 7.3.5.12.1. Key market trends, growth factors and opportunities
  - 7.3.5.12.2. Market size and forecast, by Component
  - 7.3.5.12.3. Market size and forecast, by Demography
  - 7.3.5.12.4. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Component
- 7.4.3. Market size and forecast, by Demography
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Component
  - 7.4.5.1.3. Market size and forecast, by Demography
  - 7.4.5.1.4. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Component
  - 7.4.5.2.3. Market size and forecast, by Demography
  - 7.4.5.2.4. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Component
  - 7.4.5.3.3. Market size and forecast, by Demography
  - 7.4.5.3.4. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Component
  - 7.4.5.4.3. Market size and forecast, by Demography
  - 7.4.5.4.4. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Component
  - 7.4.5.5.3. Market size and forecast, by Demography
  - 7.4.5.5.4. Market size and forecast, by End User
  - 7.4.5.6. New Zealand
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Component
  - 7.4.5.6.3. Market size and forecast, by Demography
  - 7.4.5.6.4. Market size and forecast, by End User
  - 7.4.5.7. Philippines
  - 7.4.5.7.1. Key market trends, growth factors and opportunities
  - 7.4.5.7.2. Market size and forecast, by Component
  - 7.4.5.7.3. Market size and forecast, by Demography
  - 7.4.5.7.4. Market size and forecast, by End User
  - 7.4.5.8. Rest of Asia-Pacific
  - 7.4.5.8.1. Key market trends, growth factors and opportunities
  - 7.4.5.8.2. Market size and forecast, by Component
  - 7.4.5.8.3. Market size and forecast, by Demography
  - 7.4.5.8.4. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Component
- 7.5.3. Market size and forecast, by Demography
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Component
  - 7.5.5.1.3. Market size and forecast, by Demography
  - 7.5.5.1.4. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Component
  - 7.5.5.2.3. Market size and forecast, by Demography
  - 7.5.5.2.4. Market size and forecast, by End User
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Component
  - 7.5.5.3.3. Market size and forecast, by Demography
  - 7.5.5.3.4. Market size and forecast, by End User
  - 7.5.5.4. Venezuela
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Component
  - 7.5.5.4.3. Market size and forecast, by Demography
  - 7.5.5.4.4. Market size and forecast, by End User
  - 7.5.5.5. Argentina
  - 7.5.5.5.1. Key market trends, growth factors and opportunities
  - 7.5.5.5.2. Market size and forecast, by Component
  - 7.5.5.5.3. Market size and forecast, by Demography
  - 7.5.5.5.4. Market size and forecast, by End User
  - 7.5.5.6. Rest of LAMEA
  - 7.5.5.6.1. Key market trends, growth factors and opportunities
  - 7.5.5.6.2. Market size and forecast, by Component
  - 7.5.5.6.3. Market size and forecast, by Demography
  - 7.5.5.6.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Medtronic plc
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Abbott Laboratories
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. DexCom, Inc.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Senseonics
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Key strategic moves and developments
9.5. Johnson & Johnson
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. A. Menarini Diagnostics S.r.l
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
9.7. Novo Nordisk A/S
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. GlySens Incorporated
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
9.9. Ypsomed AG
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. F. Hoffman-La Roche Ltd
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance